Glycorex Transplantation AB (publ), a medical technology company, focuses on transplantation, blood transfusion, and autoimmune diseases. It develops an antigen-specific immunoadsorption to reduce blood group antibodies and autoantibodies in the blood. The company’s principal product is Glycosorb-ABO, which enables blood group incompatible kidney transplantation and is also used to enable heart, liver, lung, and stem cell transplantation procedures. It serves in Europe, Austria, Germany, the Netherlands, the United Kingdom, Canada, and Spain. Glycorex Transplantation AB (publ) was incorporated in 1995 and is headquartered in Lund, Sweden.
Metrics to compare | GTABb | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGTABbPeersSector | |
---|---|---|---|---|
P/E Ratio | −18.8x | 0.0x | −0.5x | |
PEG Ratio | −0.27 | 0.00 | 0.00 | |
Price/Book | 4.2x | 0.0x | 2.6x | |
Price / LTM Sales | 4.6x | 0.0x | 3.2x | |
Upside (Analyst Target) | - | 0.0% | 38.8% | |
Fair Value Upside | Unlock | 0.0% | 5.4% | Unlock |